An effective serum biomarker other than the routine measurement of patients’ C-reactive protein (CRP) is thus desired as a diagnostic tool to predict the presence or absence of IBD or other forms of colitis in outpatient clinics at individuals’ initial visits. Here, CRP is linked to irritable bowel syndrome.